30 -11 (73) 2024 - Saidjalolova D.J., Sharipova M.E. - UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES IN PREGNANCY

UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES IN PREGNANCY

Saidjalolova D.J. - Tashkent Medical Academy

Sharipova M.E. - Tashkent Medical Academy

Resume

Undifferentiated connective tissue disease (UCTD) is characterized by signs and symptoms suggestive of a connective tissue disease (CTD), but not fulfilling criteria for a specific CTD. Although UCTD is probably the most common rheumatic disease diagnosed in pregnant women, data about disease course during pregnancy and perinatal outcomes are very limited. Compared to other CTDs, UCTD seems to have milder clinical manifestations in pregnancy. Its natural history is related to disease activity at conception. In fact, if the disease is in a state of remission or minimal activity at conception, pregnancy outcomes are generally good. On the contrary, patients who become pregnant in a moment of high disease activity and/or who have multiple antibodies positivity show an increased risk of disease flares, evolution to a definite CTD and obstetric complications, such as fetal growth restriction, preeclampsia and preterm birth. Therefore, a preconception assessment is essential in women with UCTD to evaluate maternal and fetal risks, to initiate interventions to optimize disease activity, and to adjust medications to those that are least harmful to the fetus. The aim of the present study was to review the available literature about pregnancy course, maternal and fetal outcomes and therapeutic approaches of pregnant women with UCTD.

Keywords: undifferentiated connective tissue disease, pregnancy, treatment, obstetric complications

First page

165

Last page

172

For citation:Saidjalolova D.J., Sharipova M.E. - UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES IN PREGNANCY//New Day in Medicine 11(73)2024 165-172 https://https://newdayworldmedicine.com/en/new_day_medicine/11-73-2024

List of References

  1. Alarcón G. S. (2000). Unclassified or Undifferentiated Connective Tissue Disease. Baillieres Best Pract. Res. Clin. Rheumatol. 2000;14:125-137. 10.1053/berh.1999.0081
  2. Alijotas-Reig J. (2013). Treatment of Refractory Obstetric Antiphospholipid Syndrome: the State of the Art and New Trends in the Therapeutic Management. Lupus 2013;22:6-17. 10.1177/0961203312465782
  3. Antunes M., Scirè C. A., Talarico R., Alexander T., Avcin T., Belocchi C., et al. (2019). Undifferentiated Connective Tissue Disease: State of the Art on Clinical Practice Guidelines. RMD Open 4, e000786. 10.1136/rmdopen-2018-000786
  4. Beneventi F., Locatelli E., Alpini C., Lovati E., Ramoni V., Simonetta M., et al. (2015). Association between Previously Unknown Connective Tissue Disease and Subclinical Hypothyroidism Diagnosed during First Trimester of Pregnancy. Fertil. Steril 2015;104:1195-1201. 10.1016/j.fertnstert.2015.07.1158
  5. Beneventi F., Locatelli E., Ramoni V., Caporali R., Montecucco C. M., Simonetta M., et al. (2012). Uterine Artery Doppler Velocimetry and Obstetric Outcomes in Connective Tissue Diseases Diagnosed during the Fi Rst Trimester of Pregnancy. //Prenat Diagn. 2012;32(11):1094-1101. 10.1002/pd.3964
  6. Bermas B. L. (2020). Safety of Rheumatic Disease Medication Use during Pregnancy and Lactation. UpToDate.
  7. Bermas B. L., Chambers C. (2021). Hydroxychloroquine Early in Pregnancy and Risk of Birth Defects: Don't Throw Out the Baby with the Bathwater. //Am. J. Obstet. Gynecol. 2021;224:548-549. 10.1016/j.ajog.2020.12.1218
  8. Bramham K., Thomas M., Nelson-Piercy C., Khamashta M., Hunt B. J. (2011). First-trimester Low-Dose Prednisolone in Refractory Antiphospholipid Antibody-Related Pregnancy Loss. Blood 2011;117:6948-6951. 10.1182/blood-2011-02-339234
  9. Cyprian F., Lefkou E., Varoudi K., Girardi G. (2019). Immunomodulatory Effects of Vitamin D in Pregnancy and beyond. Front. Immunol. 10, 2739. 10.3389/fimmu.2019.02739
  10. de Jesús G. R., Benson A. E., Chighizola C. B., Sciascia S., Branch D. W. (2020). 16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Lupus 2020;29:1601-1615. 10.1177/0961203320954520
  11. Deane K. D., El-Gabalawy H. (2014). Pathogenesis and Prevention of Rheumatic Disease: Focus on Preclinical RA and SLE. Nat. Rev. Rheumatol. 2014;10:212-228. 10.1038/nrrheum.2014.6
  12. Duan J., Ma D., Wen X., Guo Q., Gao J., Zhang G., et al. (2021). Hydroxychloroquine Prophylaxis for Preeclampsia, Hypertension and Prematurity in Pregnant Patients with Systemic Lupus Erythematosus: A Meta-Analysis. Lupus 2021;30:1163-1174. 10.1177/09612033211007199
  13. Elfving P., Marjoniemi O., Niinisalo H., Kononoff A., Arstila L., Savolainen E., et al. (2016). Estimating the Incidence of Connective Tissue Diseases and Vasculitides in a Defined Population in Northern Savo Area in 2010. Rheumatol. Int. 2016;36:917-924. 10.1007/s00296-016-3474-7
  14. Fan J., Zhong Y., Chen C. (2016). Combined Treatment of Prednisone and Aspirin, Starting before Ovulation Induction, May Improve Reproductive Outcomes in ANA-Positive Patients. Am. J. Reprod. Immunol. 2016;76:391-395. 10.1111/aji.12559
  15. Ferreira A. M., Pires C. R., Moron A. F., Araujo Júnior E., Traina E., Mattar R. (2007). Doppler Assessment of Uterine Blood Flow in Recurrent Pregnancy Loss. Int. J. Gynaecol. Obstet. 2007;98:115-119. 10.1016/j.ijgo.2007.05.006
  16. Flint J., Panchal S., Hurrell A., van de Venne M., Gayed M., Schreiber K., et al. (2016). BSR and BHPR Guideline on Prescribing Drugs in Pregnancy and Breastfeeding-Part I: Standard and Biologic Disease Modifying Anti-rheumatic Drugs and Corticosteroids. Rheumatology (Oxford) 2016;55:1693-1697. 10.1093/rheumatology/kev404
  17. Mosca M., Neri R., Bencivelli W., Tavoni A., Bombardieri S. (2002). Undifferentiated Connective Tissue Disease: Analysis of 83 Patients with a Minimum Followup of 5 Years. J. Rheumatol. 2002;29:2345-2349.
  18. Nakken B., Bodolay E., Szodoray P. (2015). Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review. Clin. Rev. Allergy Immunol. 2015;49:152-162. 10.1007/s12016-014-8452-9
  19. Østensen M., Khamashta M., Lockshin M., Parke A., Brucato A., Carp H., et al. (2006). Anti-inflammatory and Immunosuppressive Drugs and Reproduction. Arthritis Res. Ther. 2006;8:209. 10.1186/ar1957
  20. Park-Wyllie L., Mazzotta P., Pastuszak A., Moretti M. E., Beique L., Hunnisett L., et al. (2000). Birth Defects after Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies. Teratology 2000;62:385-392. 10.1002/1096-9926(200012)62:6<385:AID-TERA5>3.0.CO;2-Z

    file

    download